

Erratum

Anti-Cancer Drugs, 3, pp. 659-664

Bleomycin but not its derivatives inhibits the *in vivo* shedding of a rat tumor-associated antigen

Mark Micallef,^{CA} Toshiyuki Shibara, Masuo Hosokawa and Hiroshi Kobayashi

Figures 3 and 4 have been transposed. The correct versions are as shown:




Figure 3. *In vivo* expression of CE7 antigen by the tumor cells within the solid KMT-17 tumor after treating rats with equivalent doses of (A) BLM, (B) PEP or (C) LIB, every day for 5 days, 8 days after subcutaneous injection with tumor cells as described in the text; (D) untreated cells.




Figure 4. *In vitro* negative expression of CE7 antigen by 10% FCS A3 cells after exposure to (A) 0, (B) 500, (C) 1000 and (D) 2000 U/ml rat IFN- γ for 24 h. Similar results were obtained after treatment with TNF and IL-2 under the same experimental conditions.